| Name | Title | Contact Details |
|---|
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.
Intabio provides an analytical platform to transform and accelerate the development of biotherapeutic drugs by enabling early product quality characterization and producing profound efficiency gains across all stages of biopharmaceutical development and manufacturing.
BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible. Our proprietary molecular counting platform can accurately count DNA molecules at the single-count level to help improve disease detection.
Nines is a dynamic team applying world-class ML and AI expertise to the field of medicine.
Beacon Food Safety is a Greenwood Vlg, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.